PE20211709A1 - Anticuerpos que reconocen tau - Google Patents
Anticuerpos que reconocen tauInfo
- Publication number
- PE20211709A1 PE20211709A1 PE2021001286A PE2021001286A PE20211709A1 PE 20211709 A1 PE20211709 A1 PE 20211709A1 PE 2021001286 A PE2021001286 A PE 2021001286A PE 2021001286 A PE2021001286 A PE 2021001286A PE 20211709 A1 PE20211709 A1 PE 20211709A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- chain cdrs
- antibodies
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invencion proporciona anticuerpos que se unen especificamente a tau, donde dicho anticuerpo comprende tres CDR de cadena ligera y tres CDR de cadena pesada del anticuerpo monoclonal 9F5.. El anticuerpo 9F5 es un anticuerpo de raton caracterizado por una region variable de cadena pesada que tiene una secuencia de aminoacidos que comprende la SEQ ID NO:7 y una region variable de cadena ligera que tiene una secuencia de aminoacidos que comprende la SEQ ID NO:11. Las tres CDR de cadena pesada CDR-H1, CDR-H2 y CDR-H3 se definen por las SEQ ID NOs:8, 9 y 10, respectivamente y las tres CDR de cadena ligera CDR-L1, CDR-L2 y CDR-L3 son las definidas por las SEQ ID NOs:12, 13 y 14, respectivamente. Dichos anticuerpos inhiben o retrasan patologias relacionadas con tau y deterioro sintomatico relacionado.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803334P | 2019-02-08 | 2019-02-08 | |
| US201962813124P | 2019-03-03 | 2019-03-03 | |
| US201962855434P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/017357 WO2020163817A1 (en) | 2019-02-08 | 2020-02-07 | Antibodies recognizing tau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211709A1 true PE20211709A1 (es) | 2021-09-01 |
Family
ID=71947192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001286A PE20211709A1 (es) | 2019-02-08 | 2020-02-07 | Anticuerpos que reconocen tau |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220275067A1 (es) |
| EP (1) | EP3921343A4 (es) |
| JP (1) | JP2022520672A (es) |
| KR (1) | KR20210125037A (es) |
| CN (1) | CN113597431A (es) |
| AU (1) | AU2020219374A1 (es) |
| BR (1) | BR112021015501A2 (es) |
| CA (1) | CA3128392A1 (es) |
| CO (1) | CO2021011140A2 (es) |
| IL (1) | IL285444A (es) |
| MX (1) | MX2021009440A (es) |
| PE (1) | PE20211709A1 (es) |
| SG (1) | SG11202106717PA (es) |
| WO (1) | WO2020163817A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CN109219615B (zh) | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
| CU24636B1 (es) | 2017-05-02 | 2022-12-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2023283620A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7653100A (en) * | 1999-09-09 | 2001-04-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | A minimal tau peptide for the nucleation of paired helical filaments |
| US8754034B2 (en) * | 2009-02-06 | 2014-06-17 | The Regents Of The University Of California | Structure-based design of peptide inhibitors of amyloid fibrillation |
| EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
| GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| AU2012311234B2 (en) * | 2011-09-19 | 2017-09-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease |
| US9738709B2 (en) * | 2011-10-21 | 2017-08-22 | Ohio State Innovation Foundation | Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
| US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| CA2902026C (en) * | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| US20150253341A1 (en) * | 2014-02-10 | 2015-09-10 | Merck Sharp & Dohme Corp. | Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry |
| RU2732122C2 (ru) * | 2015-06-05 | 2020-09-11 | Дженентек, Инк. | Антитела против тау-белка и способы их применения |
| SG10201912150TA (en) * | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US11319372B2 (en) * | 2017-02-21 | 2022-05-03 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) |
-
2020
- 2020-02-07 CA CA3128392A patent/CA3128392A1/en active Pending
- 2020-02-07 SG SG11202106717PA patent/SG11202106717PA/en unknown
- 2020-02-07 US US17/429,288 patent/US20220275067A1/en active Pending
- 2020-02-07 BR BR112021015501-5A patent/BR112021015501A2/pt unknown
- 2020-02-07 JP JP2021569259A patent/JP2022520672A/ja active Pending
- 2020-02-07 AU AU2020219374A patent/AU2020219374A1/en active Pending
- 2020-02-07 CN CN202080018281.7A patent/CN113597431A/zh active Pending
- 2020-02-07 PE PE2021001286A patent/PE20211709A1/es unknown
- 2020-02-07 MX MX2021009440A patent/MX2021009440A/es unknown
- 2020-02-07 KR KR1020217028112A patent/KR20210125037A/ko unknown
- 2020-02-07 EP EP20753068.4A patent/EP3921343A4/en active Pending
- 2020-02-07 WO PCT/US2020/017357 patent/WO2020163817A1/en active Application Filing
-
2021
- 2021-08-08 IL IL285444A patent/IL285444A/en unknown
- 2021-08-24 CO CONC2021/0011140A patent/CO2021011140A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3921343A1 (en) | 2021-12-15 |
| AU2020219374A1 (en) | 2021-07-01 |
| WO2020163817A1 (en) | 2020-08-13 |
| MX2021009440A (es) | 2021-09-10 |
| CA3128392A1 (en) | 2020-08-13 |
| JP2022520672A (ja) | 2022-03-31 |
| SG11202106717PA (en) | 2021-07-29 |
| KR20210125037A (ko) | 2021-10-15 |
| EP3921343A4 (en) | 2022-12-14 |
| IL285444A (en) | 2021-09-30 |
| BR112021015501A2 (pt) | 2021-10-19 |
| CN113597431A (zh) | 2021-11-02 |
| CO2021011140A2 (es) | 2021-09-20 |
| US20220275067A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211709A1 (es) | Anticuerpos que reconocen tau | |
| CU20210073A7 (es) | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs | |
| CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
| ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
| JP2019122405A5 (es) | ||
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| RS53405B (en) | CXCR4 HUMANIZED ANTIBODIES FOR CANCER TREATMENT | |
| RU2018106456A (ru) | Антитело к epha4 | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| CO6180454A2 (es) | Anticuerpos de la egfl7 y metodos de uso | |
| AR115192A1 (es) | Anticuerpos | |
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso |